Cellular and molecular derangements can also conspire to contribute to ateriovenous access failure. These factors include heme oxygenase 1 (HO-1), oxidative stress, monocyte chemoattractant protein-1 (MCP-1), and endothelial dysfunction. A combination of human and animal model studies are beginning to shed light into these processes with the hope of providing therapy in the future.